Is capmatinib included in medical insurance? How much?

As of2024, capmatinib (Capmatinib) has not yet been launched in mainland China, so it has not been included in the national medical insurance directory, and patients cannot purchase this drug through regular domestic channels. Since it cannot be reimbursed through medical insurance, patients need to obtain capmatinib (capatinib) through overseas channels.

In overseas markets, the price of the original drug capatinib (capatinib) is relatively high. The price of capmatinib (capatinib) produced by Novartis in the United States and other countries is usually around tens of thousands of yuan. This high price is mainly due to the drug's research and development costs, clinical trial expenses and brand added value.

Faced with the high prices of original drugs, some patients choose to purchase lower-priced generic drugs. The generic drug of capmatinib produced in Laos has attracted attention because of its relatively low price, which is about 3,000 yuan. Although it is a generic drug, its ingredients and efficacy are basically the same as those of the original drug, and it has undergone strict quality control.

Whether it is the original drug or a generic drug, patients need to be under the guidance of a doctor when using capatinib. Common side effects include peripheral edema, nausea, vomiting, loss of appetite, and fatigue. Serious side effects may include interstitial lung disease, liver damage, and hyperglycemia. Therefore, patients need to undergo regular physical examinations and monitor liver function and other physiological indicators to ensure the safety and effectiveness of the drug.

With the further promotion and use of capmatinib worldwide, especially its remarkable efficacy in the treatment of MET gene-mutated non-small cell lung cancer, it is expected that more countries and regions will include it in the medical insurance system. As the market for generic drugs expands, drug prices are likely to decrease further, making such targeted treatments affordable for more patients. It is expected that capmatinib (capatinib) will be launched in mainland China as soon as possible and gradually be included in medical insurance, providing more effective treatment options for the majority of patients.